Lilly, Roche dive deep into diagnostics
Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic
tests to gin up more sales.
Home » Search
Search Results
4,410 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.Lilly to cut 170 manufacturing jobs by year’s end
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.Diagnostics division to help Lilly tailor treatments
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.SKARBECK: Short-term sizzle can’t beat consistency
To achieve outsized returns, whether in mutual funds or individual stocks, investors must avoid the hype and reliance on past outperformance.
Contract pharmaceutical research firm expands to New Jersey
Concentrics grows in spite of recession as drug companies look for help to handle patent expirations
Lilly grant helps teachers learn new science curriculum
A $1.5 million grant the the Eli Lilly and Co. Foundation will train Indiana science teachers in a new curriculum that helps
students learn through exploration and problem solving.Lilly’s Lechleiter: No change in plans
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.Men on Viagra, Cialis show triple rate of sex diseases in study
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.Lilly acquires biotech company with pancreatic drug
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.IBJ wins 9 national journalism awards
IBJ won eight awards at the Alliance of Area Business Publications’ summer conference June 26 in Indianapolis.
Daniels appoints trustees to IU, Purdue boards
Former chair of the National Endowment for the Humanities among IU appointments.
Grassley asks Lilly, peers about whistleblower treatment
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.Indiana Black Expo Summer Celebration schedule
Indiana Black Expo kicks off its 40th annual Summer Celebration July 12 with a full schedule of events.
Company news
Eli Lilly and Co. released a raft of studies Monday about its newest diabetes medicines, Byetta and its
once-weekly cousin Bydureon, which has yet to win market approval from regulators. The upshot of the studies: Patients have
lower blood-sugar levels on Bydureon than those on competing drugs or, if they don’t, they lose more weight on Bydureon.
Also, Lilly and its development partner on Byetta, Amylin Pharmaceuticals Inc., issued a study of 25,000 patients that concluded
the drug causes inflammation of the pancreas no more than other diabetes medicines. In late 2009, the U.S. Food and Drug Administration
publicized and raised concerns over a few patients who died of pancreatitis while on Byetta, but did not conclude the drug
causes pancreatitis. Meanwhile, at least one analyst predicted Indianapolis-based Lilly would acquire San Diego-based Amylin
in the next two or three years.Good news for orthopedic implant companies: Industry bellwether Biomet Inc. recorded a 10-percent spike
in sales during the three months ended May 31, the Warsaw-based company announced Monday. Its peers, including Warsaw-based
Zimmer Holdings Inc., will report their financial results about a month from now. Biomet enjoyed strong sales growth in its
bread-and-butter hip and knee replacements. Hip sales rose 10 percent and knee sales jumped 15 percent. Sales were boosted
by about 2 percent due to favorable foreign exchange rates compared with a year ago. Sales for the quarter totaled $703 million,
up from $639 million during the same quarter a year ago.WellPoint Inc. expects the health insurance market to become an “oligopoly,” according to a
presentation by the company’s vice president of investor relations. Michael Kleinman told investors last week in Boston
that the health reform law is moving the industry even more quickly toward dominance by just a few players. “There are
going to be smaller insurers that are not going to be able to survive in this marketplace,” he said. Indianapolis-based
WellPoint already insures 33 million Americans, or about one in nine. The company’s chief financial officer, Wayne DeVeydt,
said previously that he expected to be able to acquire smaller insurers, but not until after health reform fades a bit as
a political issue.Lilly’s Effient steps forward, then back
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.Marcadia enlists Lilly to help develop new diabetes drug
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.IBJ wins national journalism awards
IBJ won eight awards at the Alliance of Area Business Publications’ summer conference Saturday in Indianapolis.